NASDAQ$INTS
Intensity Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Announced first quarter 2024 financial results and provided a corporate update.
Intensity Therapeutics reported a net loss of $4.6 million for the first quarter of 2024, with research and development expenses increasing to $2.8 million and general and administrative expenses rising to $1.9 million. As of March 31, 2024, cash, cash equivalents, and marketable debt securities totaled $10.5 million, expected to fund operations through the end of the first quarter of 2025.
- INT230-6 continues to advance into late-stage clinical programs in sarcoma and breast cancer.
- Initiation of a Phase 3 study (INVINCIBLE-3) testing INT230-6 as a monotherapy for soft tissue sarcoma is planned for mid-2024.
- Initiation of a Phase 2/3 program (INVINCIBLE-4) testing INT230-6 in combination with SOC for triple negative breast cancer is planned for mid-2024.
- Cash and investments of $10.5 million are expected to fund operations through the end of the first quarter of 2025.
Headline financials
Revenue & EPS history
Intensity Therapeutics · Revenue · Quarterly
$0
Forward guidance
Intensity Therapeutics expects its cash and investments of $10.5 million to be sufficient to fund operations through the end of the first quarter of 2025.
Tailwinds
- Sufficient cash to fund operations through Q1 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2024
+0.8%
Avg return
Earnings day
-4.7%
Avg return
5 days after
+26.6%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+17.3%
Q4 2023
Best reaction
-6.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.4% | -6.7% | -26.9% | |
| Q3 2025 | -5.8% | -16.0% | -8.2% | |
| Q2 2025 | +7.2% | +15.1% | +11.9% | |
| Q1 2025 | -5.8% | -22.6% | -38.6% | |
| Q4 2024 | +0.5% | -18.3% | -18.7% | |
| Q3 2024 | -6.2% | -7.4% | -39.2% | |
| Q2 2024 | -4.2% | -11.1% | -17.1% | |
| Q1 2024 | +6.7% | +17.9% | +27.5% | |
| Q1 2023 | +6.7% | +17.9% | +27.5% | |
| Q4 2023 | +17.3% | +22.0% | +12.0% | |
| Q3 2023 | -4.0% | -22.8% | +263.2% | |
| Q3 2022 | -4.0% | -22.8% | +263.2% | |
| Q4 2022 | -0.4% | -5.1% | -19.0% | |
| Q2 2023 | -0.4% | -5.1% | -19.0% | |
| Q2 2022 | -0.4% | -5.1% | -19.0% | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro